1. Home
  2. MCHPP vs GRMLW Comparison

MCHPP vs GRMLW Comparison

Compare MCHPP & GRMLW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Microchip Technology Incorporated

MCHPP

Microchip Technology Incorporated

N/A

Current Price

$76.22

Market Cap

0.0

Sector

Technology

ML Signal

N/A

GRMLW

Greenland Mines Ltd Warrant

N/A

Current Price

$0.18

Market Cap

0.0

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MCHPP
GRMLW
Founded
N/A
N/A
Country
United States
United States
Employees
19400
5
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
MCHPP
GRMLW
Price
$76.22
$0.18
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
36.2K
11.7K
Earning Date
N/A
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$45.82
$0.10
52 Week High
$78.44
$0.37

Technical Indicators

Market Signals
Indicator
MCHPP
GRMLW
Relative Strength Index (RSI) 80.93 53.81
Support Level $57.82 $0.12
Resistance Level N/A $0.19
Average True Range (ATR) 1.74 0.06
MACD 1.58 -0.00
Stochastic Oscillator 89.25 15.19

Price Performance

Historical Comparison
MCHPP
GRMLW

About MCHPP Microchip Technology Incorporated

Microchip Technology became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.

About GRMLW Greenland Mines Ltd Warrant

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.

Share on Social Networks: